Last Updated: August 10, 2026

Details for Patent: 9,320,862


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,320,862
Title:Fluid dispensing device
Abstract:A fluid dispensing device for dispensing a fluid form medicament formulation having a viscosity of from 10 to 2000 mPa·s, is disclosed having a housing and a fluid discharge device. The fluid discharge device is arranged to be actuated by one or more levers, so as to apply a force to the fluid discharge device which is used to move a container forming part of the fluid discharge device, along a longitudinal axis of the fluid discharge device to cause actuation of a pump forming. A pre-load mechanism prevents actuation of the pump until a pre-determined force is applied to each lever of sufficient magnitude to guarantee the production of a well-developed, efficient spray from the fluid dispensing device.
Inventor(s):Michael Birsha Davies, Mark Graham Hedley, James William Godfrey
Assignee: Glaxo Group Ltd
Application Number:US14/303,773
Patent Claim Types:
see list of patent claims
Use; Formulation; Device;
Patent landscape, scope, and claims:

Scope and Claims Analysis of US Patent 9,320,862: Finger-Operable Lever Actuators with Two-Stage “Pre-Load” Profiles for Metered Fluid Medicament Discharge

US Patent 9,320,862 is directed to an actuator geometry for fluid dispensing devices that move a discharge component longitudinally only after a threshold force is reached. The core claim theme is a two-stage force-transmission surface with an initial concave, high-gradient region followed by a subsequent convex, lower-gradient region, configured so that “no significant force is transferable” longitudinally until a pre-determined input force is applied. Dependent claims narrow the profile continuity, arc geometry, and placement (one end, upper end), and further require a lever that pivots about a lower end. Combination claims add a housing that constrains transverse actuator motion relative to the device’s longitudinal axis, and specify where the follower is located (container or fitting, including a collar connected to a neck of the container).


What is US Patent 9,320,862 protecting and how broad are the independent claims?

Direct answer: Claim 1 protects a finger-operable actuating member for a fluid dispensing device that converts transverse finger force into longitudinal movement of a fluid discharge device, using a two-stage actuator-contact profile that creates a pre-load/threshold before significant longitudinal force is transmitted.

Claim 1 elements (scope map)

Claim 1 can be parsed into six functional/structural elements:

  1. Finger-operable actuating member

    • Must be manually actuated (finger operable).
  2. Transverse movement relative to a longitudinal axis

    • The actuator moves transversely with respect to the fluid discharge device’s longitudinal axis.
  3. Force application to a follower to move the discharge device longitudinally

    • Actuator engages a surface for applying the force to a follower.
    • The purpose is to move the discharge device along its longitudinal axis to discharge a fluid medicament formulation.
  4. Two-stage actuator surface profile that provides pre-load

    • A surface with a two-stage profile provides a pre-load means to prevent discharge until a pre-determined force is applied to the actuator.
  5. Specific profile shapes and ordering

    • Stage 1: initial concave high gradient profile
    • Stage 2: subsequent convex lower gradient profile
    • Key limitation: in use, no significant force is transferable along the longitudinal axis until the threshold is applied.
  6. Threshold behavior is inherent to the geometry

    • The claim does not require a specific mechanical spring or stop in the text provided, but it requires that the geometry causes the stated threshold/no-transfer behavior.

Breadth and likely infringement posture

  • Broadness on device type: “fluid dispensing device” and “fluid medicament formulation” is functional and can cover many pre-filled or metered dispensing structures, including those used in self-administration settings.
  • Confinement on actuator geometry: The two-stage profile shape (concave high gradient then convex lower gradient) and the threshold effect are the primary limiting features.
  • Confinement on force transmission directionality: The claim ties actuator transverse motion to longitudinal movement, but the distinguishing part is the pre-load via contact profile.
  • Doctrine-of-equivalents sensitivity: If a competitor achieves the same threshold/no-transfer functional result using a different profile (for example, stepped, S-curve, or different curvature order), risk depends on whether the “concave high gradient” and “convex lower gradient” limitations are treated as essential claim elements rather than results.

Internal redundancy in the provided claim set

The list includes duplicates that appear to correspond to the same dependency structure:

  • Claim 11 repeats the “both have a part-circle form” limitation.
  • Claim 12 repeats “two-stage profile disposed at one end.”
  • Claim 13 repeats “actuating member comprises a lever.” This does not change scope, but it suggests the underlying patent includes multiple dependent claim variations that land on the same geometry and placement.

How do the dependent claims narrow the scope (profile continuity, arc form, and placement)?

Direct answer: The dependent claims narrow Claim 1 by requiring: (i) a smooth breakpoint between curvature stages, (ii) both stages being part-circles, and (iii) the two-stage profile being located at one end or upper end of the lever.

Claim 2: Smooth break point between concave and convex sections

  • Requires a relatively smooth break point between the high and lower gradient profiles.
  • This is a meaningful narrowing feature: a competitor using a sharp discontinuity (step) may avoid literal coverage, though it could still be captured under equivalents if the patentee can characterize “smooth” as non-essential beyond practical transfer behavior.

Claim 3: Both profiles have part-circle form

  • Requires that the high-gradient concave and lower-gradient convex stages each have a part-circle form.
  • This narrows geometry substantially versus “any concave” / “any convex” curvature.

Claims 4 and 12: Profile disposed at one end of the actuating member

  • Limits placement: two-stage profile is located at one end.

Claims 7 and 15: Profile disposed at upper end of the lever

  • When the actuator is a lever (dependent chain through Claims 5–6 and 13–14), the profile is located at the upper end, while pivotal movement is about the lower end.

Claims 11: “Both have a part-circle form” (duplicate)

  • Reinforces the same geometric restriction.

Design-around implication: The broadest risk remains for devices using an actuator-contact surface that has (a) threshold/no-transmission behavior, (b) concave-then-convex curvature, and (c) a continuous transition. The narrowest risk is when the competitor uses non-arc curvature, discontinuous breakpoints, or places the threshold geometry at a location other than the claimed ends.


What claim language requires “pre-load” and how might courts interpret it?

Direct answer: Claim 1 uses pre-load through a structural geometry-to-function coupling: the two-stage profile provides pre-load to prevent discharge until a pre-determined force is applied, with “no significant force transferable” longitudinally until threshold.

Key interpretive anchors

  • pre-load means to prevent discharge
  • pre-determined force
  • no significant force is transferable … along the longitudinal axis until” the threshold is applied.

These phrases can be treated as functional limitations that still rely on the stated structural geometry (concave high gradient then convex lower gradient). If litigation arises, a patentee’s strongest position is that the geometry is not merely describing a result; it is defining how the force transmission is controlled.

Practical engineering mapping

  • A concave high-gradient region suggests early input engagement that increases mechanical advantage slowly or resists movement in a way that delays longitudinal actuation.
  • A convex lower-gradient region suggests a later regime that allows more effective force transfer once the actuator reaches the threshold geometry contact point.

Which embodiments are explicitly required: lever geometry and transverse pivotal actuation?

Direct answer: Dependent claims explicitly lock in a lever with pivot about a lower end and a two-stage profile at the upper end (Claims 5–7 and 13–15).

Claims 5–7 (and the repeated chain 13–15)

  • Claim 5: actuating member is a lever
  • Claim 6: lever is adapted for pivotal movement about a lower end
  • Claim 7: two-stage profile at the upper end

This structure is narrower than a generic “actuating member” and is likely the primary target for molded plastic actuator designs or hinged actuator mechanisms.

Design-around implication: Devices using a sliding button, rotating cam, flexible diaphragm, or magnetically actuated system may avoid these dependent limitations, but could still fall under Claim 1 if they still use a two-stage concave-then-convex threshold contact surface for force transmission.


What combination claims add a housing and a container/fitting follower?

Direct answer: Claims 8 and 16 add a housing that movably houses the discharge component and constrains transverse actuator motion. Claims 9–10 and 17–18 specify the follower location and, in one dependent branch, the follower is in a fitting comprising a collar connected to a neck of the container.

Housing limitation (Claims 8 and 16)

  • Actuating member is comprised in the housing.
  • Housing allows actuator movement transversely to apply force to the discharge device.

This narrows to integrated dispenser architectures where the actuator is constrained within a housing rather than an externally applied force path.

Follower location (Claims 9–10 and 17–18)

  • Claim 9: follower provided to a container or a fitting on the container
  • Claim 10: follower provided to the fitting; fitting includes a collar connected to a neck of the container

Commercial relevance: Many prefilled medicament systems use neck-and-collar interfaces or adapter collars. This limitation can be used to argue coverage for specific mechanical integration patterns.


How many claim variations exist in the provided set, and what does that suggest for claim coverage?

Direct answer: The provided list contains an independent Claim 1 and a cluster of dependent claims (2–18) focusing on:

  • geometry (smooth breakpoint; part-circle)
  • placement (one end; upper end)
  • actuator type (lever; pivotal about lower end)
  • device integration (housing)
  • follower mounting (container vs fitting; collar/neck fitting)

Coverage matrix (based on provided claims only)

Feature family Claims Coverage effect
Two-stage concave-then-convex profile with pre-load/threshold 1 Core limitation; primary novelty
Smooth transition between stages 2 Narrows geometry continuity
Part-circle form for both stages 3, 11 Narrows to arc-defined curvature
Profile at one end 4, 12 Narrows placement
Lever actuator 5, 13 Limits actuator form factor
Pivot about lower end 6, 14 Limits kinematics
Profile at upper end 7, 15 Limits placement within lever
Actuator integrated in housing with transverse motion 8, 16 Narrows system integration
Follower location on container or fitting 9, 17 Narrows where contact happens
Follower location in collar/neck fitting 10, 18 Narrows to specific container interface

Net: Claim 1 provides the broadest geometry-to-function coverage; the dependent claims tighten to specific mechanical implementations.


What is the likely technical “inventive concept” behind 9,320,862?

Direct answer: The inventive concept is a two-stage contact surface on a manually actuated member that creates a threshold (pre-load) behavior preventing premature longitudinal actuation and discharge.

Why the curvature order matters

Claim 1 specifies:

  • initial concave high gradient,
  • then convex lower gradient,
  • with negligible longitudinal force transfer before reaching a pre-determined threshold.

A competitor that swaps concave/convex order or uses a single smooth monotonic curvature without a two-stage gradient change can argue the absence of the “two-stage profile comprises” limitation. A competitor that uses two-stage behavior but with different curvature definitions may contest whether “concave high gradient” and “convex lower gradient” read on its design.


Patent landscape: what other patents typically surround this type of dispenser actuator?

Direct answer: This patent sits in a crowded device-adjacent space where most surrounding patents claim one or more of: (i) actuator geometry/threshold force mechanisms, (ii) prefilled medicament dispensing architectures with followers, (iii) lever or button actuation mechanisms, and (iv) container-neck/collar interfaces.

However, the request is specifically for “Detailed analysis of the scope and claims and patent landscape for United States Drug Patent 9,320,862,” and the only concrete data provided here is the claim set. Without the application data, assignee, prosecution history, cited references, and (critically) the Orange Book or FDA device/drug association, a complete landscape mapping (other family members, continuations, litigations, or generic/biosimilar risk) cannot be produced accurately.

Per constraints, no additional landscape assertions are included.


How might this patent affect generic or competitor entry?

Direct answer: For products using a fluid dispensing medicament device, the main legal threat is not “generic drug substitution” but mechanical and method substitution risk: copying the actuator’s two-stage threshold force-transmission geometry, even if the medicament formulation is different.

  • Risk to competitors: Dispensers that use a finger-actuated lever (or equivalent transverse actuator) applying force to a follower via a two-stage concave/convex surface that prevents discharge until a force threshold is reached.
  • Lower risk: Designs that use different threshold mechanisms (e.g., purely mechanical stops, elastomeric delay, different cam geometry without the claimed two-stage concave-convex profile), or designs that change follower mounting away from container/fitting collar/neck interfaces (relevant only to those dependent claims).

When does exclusivity end and what is the enforcement timeline?

Direct answer: The provided prompt does not include filing date, priority date, patent term adjustments, or terminal disclaimer terms for US 9,320,862, so a correct end-of-exclusivity timetable cannot be stated.


Key Takeaways

  • US 9,320,862 Claim 1 protects a finger-operated actuator that moves transversely, applies force to a follower, and drives longitudinal discharge only after a pre-determined threshold force using a two-stage concave-then-convex, gradient-based contact profile.
  • Dependent claims narrow scope around: smoothness at the breakpoint, part-circle geometry for both curvature stages, placement at one end/upper end, lever form and pivotal lower-end movement, and system integration via a housing and a follower on a container fitting with collar/neck.
  • The practical litigation focus is likely the force-transmission threshold behavior and whether the accused design’s actuator-contact geometry reads on “initial concave high gradient” followed by “subsequent convex lower gradient,” including whether the break is smooth and whether curvature is arc-based.

FAQs

1) What actuator designs are closest to US 9,320,862’s Claim 1?
Transverse finger-actuated lever or button mechanisms that engage a follower with a two-stage contact surface producing delayed longitudinal force transfer until a threshold is reached.

2) Does Claim 1 require a lever, or can the actuator be other shapes?
Claim 1 covers a “finger-operable actuating member.” The lever requirement appears only in dependent claims.

3) What does “two-stage profile” mean legally in Claim 1?
It is a structural limitation requiring an initial concave high-gradient region followed by a subsequent convex lower-gradient region that produces the pre-load/threshold behavior.

4) How can a competitor design around the “pre-load means” aspect?
By altering the force transmission so that discharge is not delayed by the specific two-stage concave-then-convex gradient contact profile that yields “no significant force transferable” longitudinally before threshold.

5) Are the collar/neck and housing limitations necessary for all infringement?
No. They appear in dependent claims. They are required only if asserting those specific narrower claim scopes.


References (APA)

No sources were cited because no bibliographic or evidentiary material beyond the provided claim text was included.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,320,862

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,320,862

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0325629.4Nov 3, 2003
United Kingdom0405477.1Mar 11, 2004
United Kingdom0420539.9Sep 17, 2004

International Family Members for US Patent 9,320,862

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 534589 ⤷  Start Trial
Australia 2004287261 ⤷  Start Trial
Australia 2005221876 ⤷  Start Trial
Australia 2010201953 ⤷  Start Trial
Australia 2010246483 ⤷  Start Trial
Brazil PI0416128 ⤷  Start Trial
Brazil PI0508586 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.